DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Treatment with the multiple sclerosis (MS) drug alemtuzumab (Lemtrada, Genzyme/Sanofi) is associated with thyroid dysfunction and an increased risk of Graves disease that may have onset later than previously thought and therefore could require longer-term monitoring, according to results of one of the largest case series to date, spanning 20 years.
“Alemtuzumab is a highly effective therapy for relapsing-remitting MS, [with a] number needed to treat to benefit of five [and] number needed to treat for a serious adverse event of 148,” say Nadia Pariani, University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, United Kingdom, and colleagues.
“However, the development of thyroid autoimmunity months or years after treatment is a frequent complication, requiring ongoing biochemical surveillance for at least 4 years after alemtuzumab therapy to detect and treat thyroid dysfunction promptly,” they note in their article published in the Journal of Clinical Endocrinology and Metabolism.
People & PlacesTerry Jay Smith, MDDr. Terry J. Smith, the Frederick G.L. H...
Evidence & EducationSelenium in Graves Hyperthyroidism and OrbitopathyPurpose: To review the in vitro and in ...
People & PlacesUniversity of Miami Health SystemWe leverage the latest research complete...
People & PlacesVahab Fatourechi, MDVahab Fatourechi is an endocrinologist-i...
Evidence & EducationHyperthyroid Patients Without Graves’ Orbitopathy are not at Increased Risk of Developing Glaucoma: A Nationwi...Purpose: Graves' disease (GD) and toxic...
Evidence & EducationPredicting Risk of Recurrent Thyrotoxicosis Following Thionamide Withdrawal in Graves’ DiseaseBackground/Aim: Thionamides are a safe ...
Videos & VisualsTop 3 Exercise Tips for a Healthy Thyroidhttps://www.youtube.com/watch?v=2DayLHOs...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.